Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Cash: 2016-2025

Historic Change in Cash for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $26.1 million.

  • Ultragenyx Pharmaceutical's Change in Cash rose 107.89% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.5 million, marking a year-over-year decrease of 33.23%. This contributed to the annual value of -$35.2 million for FY2024, which is 143.08% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Change in Cash stood at $26.1 million, which was down 47.33% from $49.5 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Change in Cash high stood at $367.9 million for Q2 2024, and its period low was -$330.0 million during Q3 2024.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Change in Cash value was $16.1 million (recorded in 2023), while the average stood at $7.0 million.
  • Examining YoY changes over the last 5 years, Ultragenyx Pharmaceutical's Change in Cash showed a top increase of 2,179.24% in 2024 and a maximum decrease of 1,035.71% in 2024.
  • Ultragenyx Pharmaceutical's Change in Cash (Quarterly) stood at $100.0 million in 2021, then crashed by 358.59% to -$258.7 million in 2022, then skyrocketed by 154.42% to $140.8 million in 2023, then slumped by 82.99% to $23.9 million in 2024, then soared by 107.89% to $26.1 million in 2025.
  • Its Change in Cash stands at $26.1 million for Q3 2025, versus $49.5 million for Q2 2025 and -$45.0 million for Q1 2025.